Ciprofibrate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ciprofibrate
Accession Number
DB09064
Type
Small Molecule
Groups
Approved, Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • ciprofibrato
External IDs
WIN 35833 / WIN-35833
Categories
UNII
F8252JGO9S
CAS number
52214-84-3
Weight
Average: 289.15
Monoisotopic: 288.0319997
Chemical Formula
C13H14Cl2O3
InChI Key
KPSRODZRAIWAKH-UHFFFAOYSA-N
InChI
InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)
IUPAC Name
2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid
SMILES
CC(C)(OC1=CC=C(C=C1)C1CC1(Cl)Cl)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UPeroxisome proliferator-activated receptor alphaNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Ciprofibrate is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Ciprofibrate is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Ciprofibrate is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when Ciprofibrate is combined with Acenocoumarol.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Ciprofibrate is combined with Acetohexamide.
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Ciprofibrate.
Alendronic acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ciprofibrate.
Aluminium clofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Aluminium clofibrate.
AmiodaroneThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amiodarone is combined with Ciprofibrate.
Amphotericin BThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ciprofibrate.
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D03521
ChemSpider
2661
BindingDB
50371235
ChEBI
50867
ChEMBL
CHEMBL557555
Drugs.com
Drugs.com Drug Page
Wikipedia
Ciprofibrate
ATC Codes
C10AB08 — Ciprofibrate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingBasic ScienceDiastolic Dysfunction / Impaired Glucose Metabolism / Myocardial Insulin Sensitivity1
4CompletedTreatmentDyslipidemias / High Blood Pressure (Hypertension)1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension) / Hypertriglyceridemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00779 mg/mLALOGPS
logP3.97ALOGPS
logP3.62ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.69ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity70.5 m3·mol-1ChemAxon
Polarizability28.08 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenoxyacetic acid derivatives
Direct Parent
Phenoxyacetic acid derivatives
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Monocarboxylic acids and derivatives / Carboxylic acids / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Alkyl chlorides
Substituents
Phenoxyacetate / Phenoxy compound / Phenol ether / Alkyl aryl ether / Carboxylic acid derivative / Carboxylic acid / Ether / Monocarboxylic acid or derivatives / Organic oxygen compound / Organohalogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
ring assembly (CHEBI:50867)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ: Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci. 2006 Aug;92(2):476-89. Epub 2006 May 26. [PubMed:16731579]

Drug created on May 11, 2015 16:28 / Updated on November 02, 2018 06:57